Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06997016

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

The goal of this interventional study is to learn if an Enhanced Recovery After Surgery (ERAS) protocol works to reduce the need for narcotic pain medications in live donor kidney transplant recipients. The main questions it aims to answer are:

Does the ERAS protocol lower the amount of opioid narcotic medication needed to manage post-surgery pain? Does the ERAS protocol help lower pain scores after surgery? Researchers will compare the ERAS protocol to previous patients where the ERAS protocol was not used to see if the ERAS protocol works to reduce post-surgery pain.

Participants will be asked to:

* Drink a pre-surgery carbohydrate drink two hours before your surgery. * Take a pre-surgery dose of Tylenol by mouth. * Take a pre-surgery dose of Gabapentin by mouth. * The surgeon will administer a local numbing medication at the surgery site by injection during the surgery. * Begin walking with assistance about 12 hours after your surgery. * Allow the research staff to collect data about your kidney function. This data will be collected on your postoperative clinic visits, which generally occur about twice weekly for one month. This information will determine your kidney health, need for hospitalization, and side effects that may occur.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Baylor Scott & White All Saints Medical Center

Fort Worth, Texas, 76104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients
  • over 18 years of age
  • receiving a kidney transplant from a living donor.

Exclusion criteria

  • delayed gastric emptying
  • severe type I diabetes
  • allergy to interventional medications
  • pregnancy (this is a normal exclusion for kidney recipients)

Treatment and study plan

pre-operative carbohydrate drink

Dietary Supplement

50 g of carbohydrate drink 2 hours before surgery

Acetaminophen

Drug

650mg acetaminophen 30 minutes prior to surgery

Other names: tylenol

Gabapentin

Drug

300 mg gabapentin 30 minutes prior to surgery

Other names: Neurontin, Gralise

Bupivacaine

Drug

intraoperative local anesthetic

Other names: Marcaine, Sensorcaine

Ambulation

Other

Assisted ambulation 12 hours after surgery

Primary outcomes

  1. Numerical Rating Scale (NRS) (0-10)

    Time frame: From enrollment to the end of treatment at 30 days

    Patient reported pain on a scale from 0 (no pain) to 10 (the worst possible pain)

  2. Narcotic Use

    Time frame: From enrollment to the end of treatment at 30 days

    milligram morphine equivalents (MME)

Secondary outcomes

  1. Adverse Events

    Time frame: From enrollment to the end of treatment at 30 days

    unfavorable medical occurence

  2. Hospital readmission

    Time frame: From enrollment to the end of treatment at 30 days

    readmission to any hospital within 30 days

  3. Length of Stay

    Time frame: From enrollment to the end of treatment at 30 days

    total hospital length of stay

Sponsors and collaborators

Lead sponsor

Baylor Research Institute

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
May 30, 2025
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.